Grifols (GIFLF) EPS (Diluted) Growth (1y) (2014 - 2025)
Powered by 
Analysis
Grifols (GIFLF) EPS (Diluted) Growth (1y) (2014 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 64.94% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -640.40% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 8.02% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -4.52% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 89.89% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 315.14% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -84.85% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 155.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 155.09% |
| Dec 31, 2024 | 29.25% |
| Dec 31, 2023 | -99.93% |
| Dec 31, 2022 | 218.05% |
| Dec 31, 2021 | -8.96% |
| Dec 31, 2020 | -124.65% |
| Mar 31, 2020 | 69.41% |
| Dec 31, 2019 | -1.63% |
| Mar 31, 2019 | -26.28% |
| Dec 31, 2018 | -7.41% |
| Jun 30, 2018 | 32.44% |
| Mar 31, 2018 | 6.55% |
| Dec 31, 2017 | 486.30% |
| Jun 30, 2017 | 0.54% |
| Mar 31, 2017 | -20.48% |
| Dec 31, 2016 | 5.13% |
| Sep 30, 2016 | 1.67% |
| Jun 30, 2016 | 7.21% |
| Mar 31, 2016 | 115.09% |
| Dec 31, 2015 | -12.61% |